A new drug has been approved in Scotland that brings hope to individuals at risk of losing their sight due to a common eye condition. Macular oedema is characterized by the swelling of the retina at the back of the eye, usually caused by fluid build-up from the leakage of damaged or abnormal blood vessels. This condition can be associated with various retinal diseases or occur as a result of inflammation following eye surgery or trauma. While macular oedema is considered incurable, early diagnosis can lead to effective treatment.
Two conditions that can predispose individuals to macular oedema are central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Within two months of being diagnosed, 85% of individuals with BRVO and 75% with CRVO develop macular oedema. The Scottish Medicines Consortium has granted approval for the use of Vabysmo to treat adults with visual impairment caused by macular oedema resulting from BRVO or CRVO.
Eelke Roos, the Ophthalmology Lead at Roche Products Limited, expressed delight at the Consortium’s decision, stating that patients with macular oedema due to retinal vein occlusion now have access to Vabysmo. Roos highlighted the potential of this medication to reduce the treatment burden on patients, caregivers, and the healthcare system by decreasing the frequency of injections and hospital visits required.
The approval of this new drug offers a glimmer of hope to those grappling with the challenges of macular oedema. Patients and healthcare professionals alike welcome this advancement in treatment for a condition that threatens one’s eyesight. This development underscores the importance of ongoing research and innovation in the field of ophthalmology to improve the quality of life for individuals at risk of sight loss.